PUBLISHED ON: April 16, 2015 | Duration: 13 min, 08 sec
Mayuresh Joshi, fund manager at Angel Broking, is bullish on Sun Pharmaceutical Industries from a long-term perspective. After its merger with Ranbaxy, the bias remains in favour of the merged entity in terms of its earnings growth, he adds.
